Perkembangan targeted therapy pada kanker payudara dengan pertimbangan luaran biaya dan kualitas hidup: narrative review

Candra Eka Puspitasari; Janatul Annisa; Malva Marshaniswa Yasykurah; Baiq Hawarikatun

doi:10.29303/sjp.v5i2.448

Perkembangan targeted therapy pada kanker payudara dengan pertimbangan luaran biaya dan kualitas hidup: narrative review

Penulis

Candra Eka Puspitasari , Janatul Annisa , Malva Marshaniswa Yasykurah , Baiq Hawarikatun

DOI:

10.29303/sjp.v5i2.448

Diterbitkan:

2024-09-30

Terbitan:

Vol 5 No 2 (2024): September

Kata Kunci:

breast cancer, chemotherapy, cost, targeted therapy, quality of life

Articles

##submission.downloads##

PDF (English)

Cara Mengutip

Puspitasari, C. E., Annisa, J., Yasykurah, M. M., & Hawarikatun, B. (2024). Perkembangan targeted therapy pada kanker payudara dengan pertimbangan luaran biaya dan kualitas hidup: narrative review . Sasambo Journal of Pharmacy, 5(2), 124–131. https://doi.org/10.29303/sjp.v5i2.448

Unduh Sitasi

Abstrak

Breast cancer is a malignant tumour that grows in the breast tissue and can spread to the lymph nodes and metastasize to other parts of the body. Targeted therapy is currently developed as a therapeutic management for breast cancer with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-). This review aims to determine the effectiveness both in terms of clinical and cost on the use of single or combined targeted therapy when compared with conventional therapy, namely chemotherapy in breast cancer patients. The results show that the use of targeted therapy can provide greater health benefits in both single and combination use even though it can increase the cost of therapy.

Referensi

Bradley, R., Braybrooke, J., Gray, R., Hills, R., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., Taylor, C., Anderson, S., Gelber, R., Gianni, L., Jacot, W., Joensuu, H., Moreno-Aspitia, A., Piccart, M., Press, M., … Swain, S. M. (2021). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. The Lancet Oncology, 22(8), 1139–1150. https://doi.org/10.1016/S1470-2045(21)00288-6

Chicaíza-Becerra, L., García-Molina, M., Gamboa, O., & Castañeda-Orjuela, C. (2014). ErbB2+metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country. Revista de Salud Publica, 16(2), 270–280. https://doi.org/10.15446/rsap.v16n2.31690

Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., Iwata, H., Hamilton, E., Curigliano, G., Xu, B., Huang, C.-S., Kim, J. H., Chiu, J. W. Y., Pedrini, J. L., Lee, C., … Hurvitz, S. A. (2022). Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. New England Journal of Medicine, 386(12), 1143–1154. https://doi.org/10.1056/nejmoa2115022

Dalal, A. A., Gagnon-Sanschagrin, P., Burne, R., Guérin, A., Gauthier, G., Small, T., & Niravath, P. (2018). Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer. Advances in Therapy, 35(6), 768–778. https://doi.org/10.1007/s12325-018-0701-5

Danese, M. D., Masaquel, A., Santos, E., Brammer, M., Lee, A., & Lalla, D. (2015). Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States. Value in Health, 18(6), 876–883. https://doi.org/10.1016/j.jval.2015.06.003

GLOBOCAN. (2022). Global Cancer Observatory – Cancer Today-WORLD. International Agency for Research on Cancer. https://gco.iarc.who.int/

Haddad, T. C., He, J., Sullivan, C. C. O., Chen, B., Northfelt, D., Dueck, C., Ballman, K. V, Tenner, K. S., Linden, H., Sparano, J. A., Hopkins, J. O., Silva, C. De, Perez, E. A., Haluska, P., & Goetz, M. P. (2021). Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance). Department of Health and Human Servis USA, 188(2), 477–487. https://doi.org/10.1007/s10549-021-06221-8.Randomized

Ketut, S., & Kartika, S. M. K. . (2022). Kanker Payudara: Diagnostik, Faktor Risiko, Dan Stadium. Ganesha Medicine, 2(1), 42–48. https://doi.org/10.23887/gm.v2i1.47032

Khoirunnisa, S. M., Suryanegara, F. D. A., Setiawan, D., Postma, M. J., & de Jong, L. A. (2024). Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis. PLoS ONE, 19(5), 1–16. https://doi.org/10.1371/journal.pone.0304483

Kreutzfeldt, J., Rozeboom, B., Dey, N., & De, P. (2020). The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. American Journal of Cancer Research, 10(4), 1045–1067. http://www.ncbi.nlm.nih.gov/pubmed/32368385%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7191090

Masoud, V., & Pagès, G. (2017). Targeted therapies in breast cancer: New challenges to fight against resistance. World Journal of Clinical Oncology, 8(2), 120–134. https://doi.org/10.5306/wjco.v8.i2.120

Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolma rk, N., Rastogi, P., Schneeweiss, A., Redondo, A., Fischer, H. H., Jacot, W., Conlin, A. K., Arce-Salinas, C., Wapnir, I. L., Jackisch, C., DiGiovanna, M. P., Fasching, P. A., Crown, J. P., … Geyer, C. E. (2019). Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medicine, 380(7), 617–628. https://doi.org/10.1056/nejmoa1814017

Mueller, V., Wardley, A., Paplomata, E., Hamilton, E., Zelnak, A., Fehrenbacher, L., Jakobsen, E., Curtit, E., Boyle, F., Harder Brix, E., Brenner, A., Crouzet, L., Ferrario, C., Muñoz-Mateu, M., Arkenau, H. T., Iqbal, N., Aithal, S., Block, M., Cold, S., … Gelmon, K. (2021). Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). European Journal of Cancer, 153(January), 223–233. https://doi.org/10.1016/j.ejca.2021.05.025

NCCN. (2023). Stage_Iv_Breast-Patient.Pdf (p. 82). National Comprehensive Cancer Network.

Ngan, T. T., Ngoc, N. B., Van Minh, H., Donnelly, M., & O’Neill, C. (2022). Costs of breast cancer treatment incurred by women in Vietnam. BMC Public Health, 22(1), 1–10. https://doi.org/10.1186/s12889-021-12448-3

Rochlitz, C., Bigler, M., von Moos, R., Bernhard, J., Matter-Walstra, K., Wicki, A., Zaman, K., Anchisi, S., Küng, M., Na, K. J., Bärtschi, D., Borner, M., Rordorf, T., Rauch, D., Müller, A., Ruhstaller, T., Vetter, M., Trojan, A., Hasler-Strub, U., … Winterhalder, R. (2016). SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III tr. BMC Cancer, 16(1), 1–8. https://doi.org/10.1186/s12885-016-2823-y

Sarkar, S., & Bhatia, G. (2021). Writing and appraising narrative reviews. Journal of Clinical and Scientific Research, 169–172. https://doi.org/10.4103/JCSR.JCSR

Swain et al. (2017). Breast Cancer Treatment Regimens. HMInc, 9(8), 1–6. https://doi.org/10.1056/NEJMoa1413513.Pertuzumab

Takumoto, Y., Shiroiwa, T., Shimozuma, K., Iwata, H., Takahashi, M., Baba, S., Kobayashi, K., Hagiwara, Y., Kawahara, T.,

Uemura, Y., Mukai, H., Taira, N., & Sawaki, M. (2022). Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial. Clinical Drug Investigation, 42(3), 253–262. https://doi.org/10.1007/s40261-022-01124-y

Trayes, K. P., & Cokenakes, S. E. . (2021). Breast cancer treatment. American Family Physician, 10(3), 145–153.

Yang, J., Han, J., Zhang, Y., Muhetaer, M., Chen, N., & Yan, X. (2022). Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer. Frontiers in Pharmacology, 13(September). https://doi.org/10.3389/fphar.2022.924126

Lisensi

Artikel ini berlisensi Creative Commons Attribution 4.0 International License.

Authors who publish with Sasambo Journal of Pharmacy (SJP), agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Lisensi Creative Commons Atribusi 4.0 Internasional. This license allows authors to use all articles, data sets, graphics and appendices in data mining applications, search engines, web sites, blogs, and other platforms by providing an appropriate reference. The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Sasambo Journal of Pharmacy
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Perkembangan targeted therapy pada kanker payudara dengan pertimbangan luaran biaya dan kualitas hidup: narrative review

Penulis

DOI:

Diterbitkan:

Terbitan:

Kata Kunci:

Articles

##submission.downloads##

Cara Mengutip

Abstrak

Referensi

Lisensi

Terbitan Terkini

Informasi

Dikembangkan Oleh

Official Website Of

Jurnal Farmasi, Fakultas Kedokteran, Universitas Mataram

Contact Us

Official link

Share & Follow